We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

100 hedge funds and large institutions have $303M invested in Y-mAbs Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

10% more funds holding

Funds holding: 91 → 100 (+9)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

2.75% less ownership

Funds ownership: 56.64% → 53.89% (-2.8%)

8% less capital invested

Capital invested by funds: $330M → $303M (-$26.8M)

Holders
100
Holders Change
+9
Holders Change %
+9.89%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
29
Reduced
32
Closed
7
Calls
$1.78M
Puts
–
Net Calls
+$1.78M
Net Calls Change
-$802K

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$4.92M
2
State Street
State Street
Massachusetts
+$2.91M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.5M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.29M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.23M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.81M
3
PCH
Polar Capital Holdings
United Kingdom
-$6.97M
4
Morgan Stanley
Morgan Stanley
New York
-$1.97M
5
Invesco
Invesco
Georgia
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.5M -$67.3K -4,062 -4%
Bank of America
27
Bank of America
North Carolina
$1.49M +$574K +34,679 +50%
ACM
28
Ashford Capital Management
Delaware
$1.47M -$36.9K -2,230 -2%
Rafferty Asset Management
29
Rafferty Asset Management
New York
$1.47M +$848K +51,228 +101%
Citigroup
30
Citigroup
New York
$1.36M +$585K +35,354 +60%
RHJA
31
Rice Hall James & Associates
California
$1.31M -$20.4K -1,233 -1%
Citadel Advisors
32
Citadel Advisors
Florida
$1.3M +$1.5M +90,460 New
SCM
33
Soleus Capital Management
Connecticut
$1.26M -$811K -49,000 -36%
Swiss National Bank
34
Swiss National Bank
Switzerland
$1.11M – – –
State of Wisconsin Investment Board
35
State of Wisconsin Investment Board
Wisconsin
$1.11M -$369K -22,277 -22%
Ameriprise
36
Ameriprise
Minnesota
$973K -$33.7K -2,036 -3%
Barclays
37
Barclays
United Kingdom
$929K +$1.02M +61,634 +2,193%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$675K +$54.5K +3,294 +8%
UOC
39
UBS O'Connor
Illinois
$634K +$729K +44,000 New
Connor, Clark & Lunn Investment Management (CC&L)
40
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$632K +$129K +7,798 +22%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$616K -$13.3K -803 -2%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$608K – – –
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$563K +$514K +31,031 +389%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$558K +$282K +17,042 +79%
JP Morgan Chase
45
JP Morgan Chase
New York
$491K +$21.8K +1,315 +4%
Victory Capital Management
46
Victory Capital Management
Texas
$476K +$546K +32,990 New
SO
47
STRS Ohio
Ohio
$419K +$41.4K +2,500 +9%
VOYA Investment Management
48
VOYA Investment Management
Georgia
$410K – – –
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
$407K +$468K +28,251 New
Walleye Trading
50
Walleye Trading
New York
$384K +$441K +26,607 New
1
2
3 4 5

YMAB Hedge Fund Activity: Q3 2022 in Review

100 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2022, worth a combined $303M — down 8.1% from $330M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new YMAB positions and 7 closed out — a net gain of 9 holders — while 29 added to existing stakes and 32 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $4.92M. The largest seller was AllianceBernstein, cutting an estimated $11M.

  • 100 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2022, up from 91 in Q2 2022.
  • Funds reported $303M of Y-mAbs Therapeutics stock for Q3 2022, down 8.1% quarter-over-quarter.
  • 16 funds opened new Y-mAbs Therapeutics positions in Q3 2022 and 7 closed out, a net change of +9 holders.
  • The largest Y-mAbs Therapeutics buyer in Q3 2022 was Driehaus Capital Management, an estimated $4.92M added.
  • The largest Y-mAbs Therapeutics seller in Q3 2022 was AllianceBernstein, an estimated $11M sold.

Based on aggregated 13F filings for Q3 2022.